Clinical trial
A First in Human, Single Dose, Safety and Tolerability Study of MKC253…
NCT00475371 · Mannkind Corporation, Industry · Completed
Key facts
| NCT number | NCT00475371 |
|---|---|
| Title | A First in Human, Single Dose, Safety and Tolerability Study of MKC253 Inhalation Powder in Healthy Adult Males |
| Official title | A Phase 1a, Single-Dose, Open-Label, Parallel, Ascending Dose, Controlled Safety and Tolerability Trial of Inhaled MKC253 in Healthy Adult Male Subjects |
| Lead sponsor | Mannkind Corporation, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2, Healthy Males |
| Intervention type | Drug |
| Interventions | MKC253 Inhalation Powder |
| Enrollment | 26 |
| Start date | Apr 1, 2007 |
| Primary completion | Jun 1, 2007 |
| First posted | May 21, 2007 |
| Last update posted | Jun 14, 2012 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: